Chengdu Mingde Zhiyuan Pharmaceutical Technology Co., Ltd.

Primary objective: To evaluate the bioequivalence of the test formulation [Cirnidipine tablets, 10 mg, developed by Chengdu Mingde Zhiyuan Pharmaceutical Technology Co., Ltd.] and the reference formulation [Cirnidipine tablets, 10 mg, certified by EA Pharma Co., Ltd./EA Farma Co., Ltd.; trade name: Atelec®] in healthy Chinese subjects under fasting conditions, using the main pharmacokinetic parameters (AUC and Cmax) as bioequivalence indicators. Secondary objective: To observe the safety of the test and reference formulations under fasting conditions.

Primary objective: To evaluate the bioequivalence of the test formulation (mianserin hydrochloride tablets, 30 mg, developed by Chengdu Mingde Zhiyuan Pharmaceutical Technology Co., Ltd.) and the reference formulation (mianserin hydrochloride tablets, 30 mg, certified by MSD K.K.; trade name: Tetramide®) in fasting and postprandial subjects in healthy Chinese trial participants, using the primary pharmacokinetic parameters (AUC and Cmax) as bioequivalence indicators. Secondary objective: To observe the safety of the test and reference formulations in fasting and postprandial states.

The bioequivalence of the test formulation (10 mg cilnidipine tablets, registered by Chengdu Mingde Zhiyuan Pharmaceutical Technology Co., Ltd.) and the reference formulation (10 mg cilnidipine tablets, licensed by EA Pharma Co., Ltd.; trade name: Atelec®) was evaluated in healthy Chinese volunteers using the key pharmacokinetic parameters (AUC and Cmax) of cilnidipine as bioequivalence indicators in both fasting and fed conditions. Secondary objective: To observe the safety of the test and reference formulations in both fasting and fed conditions.